# A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency

> **NCT05783557** · PHASE3 · UNKNOWN · sponsor: **CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.** · enrollment: 398 (estimated)

## Conditions studied

- Hypertensive Emergency

## Interventions

- **DRUG:** Clevidipine Butyrate Injectable Emulsion
- **DRUG:** Cleviprex®

## Key facts

- **NCT ID:** NCT05783557
- **Lead sponsor:** CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 398 (ESTIMATED)
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05783557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05783557, "A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05783557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*